TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02008565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
Study: NCT02500004

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.

Intervention type: RADIATION
Group type: OTHER
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.
Study: NCT01986556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 2, Lot A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 2, Lot A)
Study: NCT02500004

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG PET-MRI-imaging
Description: BAT activity: 18F-FDG PET-MRI-imaging.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.
Study: NCT02008565

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anal exercises with biofeedback
Description: Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Anal exercises with biofeedback
Description: Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
Study: NCT04414605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gu Ben Hua Yu Fang decoction (Chinese herbal medicine)
Description: Chinese herbal formula (Gu Ben Hua Yu Fang) decoction will be orally administrated twice daily. One pack of Gu Ben Hua Yu Fang will be taken for each time. Chinese herbal medicine (Gu Ben Hua Yu Fang) will not be used on the day of receiving secukinumab injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab Auto-Injector [Cosentyx]
Description: Secukinumab will be administered by subcutaneous injection. The required dose (300 mg) is divided into two doses of 150 mg (contained in two separate syringes), which are injected at the same time. The first five doses (each consisting of 2 injections of 150 mg) are given at weekly intervals, with subsequent treatment given monthly (2 injections of 150 mg).
Study: NCT02499718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP mode
Description: Noninvasive ventilator
Study: NCT02500004

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.

Intervention type: RADIATION
Group type: OTHER
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.
Study: NCT02123290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSM265 ymg
Description: Dose of DSM265 to be determined based on the results of the second cohort
Study: NCT02500004

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DXA scanning
Description: Body composition: DXA scanning, D2O and MRI.
Study: NCT04773886

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
Study: NCT02500004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Study: NCT02904837

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Study: NCT02461823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconia crown
Description: patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Porcelain metal crown
Description: patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
Study: NCT04035603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: 50 mg d-cycloserine given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: matching 50 mg identical placebo given as an augmentation agent, 70 minutes prior to three CET sessions for participants who achieved smoking cessation following open treatment.
Study: NCT02500004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal subcutaneous adipose tissue biopsy
Description: Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
Study: NCT01986556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (Site 2, Lot B)
Study: NCT02500004

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Systemic inflammatory profile: blood sampling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.

Intervention type: OTHER
Group type: OTHER
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Indirect calorimetry
Description: Resting metabolic rate: indirect calorimetry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry
Description: Physical activity level: accelerometry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry
Description: Physical activity level: accelerometry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry
Description: Physical activity level: accelerometry.

Intervention type: DEVICE
Group type: OTHER
Intervention: Accelerometry
Description: Physical activity level: accelerometry.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometry
Description: Physical activity level: accelerometry.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.

Intervention type: OTHER
Group type: OTHER
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Double-labeled water
Description: Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
Study: NCT04959357

Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional speckle tracking imaging
Description: lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional speckle tracking imaging
Description: lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging

Intervention type: DIAGNOSTIC_TEST
Intervention: Two dimensional speckle tracking imaging
Description: lobal longitudinal strain and strain rate, subendocardial LS and subepicardial LS were quantified by two dimensional speckle tracking imaging
Study: NCT02054182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
Study: NCT02244242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Study: NCT02720757

Intervention type: DRUG
Intervention: Spiolto Respimat
Description: Tiotropium bromide + Olodaterol
Study: NCT00892801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Description: Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
Study: NCT04067570

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic body radiation therapy, or SBRT, is a cancer treatment that delivers extremely precise, very intense doses of radiation to cancer cells while minimizing damage to healthy tissue
Study: NCT04881942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product A
Description: e-Vapor product XL25F
Study: NCT04929990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory muscle training
Description: Inspiratory and expiratory muscle training were performed using a breathing trainer (Dofin DT11/14, Galemed Co. Ltd, Taiwan) for 30 minutes a day with a total of eight weeks. Before the training, the MIP and maximal expiratory pressure (MEP) were documented by the best performance of three trials with a digital pressure gauge (GB60, Jitto International Co. Ltd, Taiwan)
Study: NCT01099228

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 131-I MIBG and 111-In pentetreotide
Description: Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 131-I MIBG and In-111 DOTATATE
Description: 131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
Study: NCT03043833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Wellbeing Course
Description: The Wellbeing Course (Titov et al., 2011) includes five online lessons:~* Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.~* Lesson 2 presents different strategies to generate realistic cognitions.~* Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.~* Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.~* Lesson 5 is about problem solving, relapse prevention and staying well.~For each lesson, a Do It Yourself guide is included as well vignettes and additional material.
Study: NCT04213755

Intervention type: DIAGNOSTIC_TEST
Intervention: ROTEM
Description: ROTEM including INTEM, EXTEM, APTEM, and FIBTEM
Study: NCT04881942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product A
Description: e-Vapor product XL25F

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product A
Description: e-Vapor product XL25F

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product A
Description: e-Vapor product XL25F

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product B
Description: e-Vapor product XL40CB
Study: NCT04773886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mineral trioxide aggregate
Description: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
Study: NCT03280979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rescue regimen
Description: In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
Study: NCT04881942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product B
Description: e-Vapor product XL40CB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product B
Description: e-Vapor product XL40CB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product B
Description: e-Vapor product XL40CB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product C
Description: e-Vapor product XL35WM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product C
Description: e-Vapor product XL35WM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product C
Description: e-Vapor product XL35WM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product C
Description: e-Vapor product XL35WM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product D
Description: e-Vapor product XL40MB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product D
Description: e-Vapor product XL40MB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product D
Description: e-Vapor product XL40MB

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Vapor Product D
Description: e-Vapor product XL40MB
Study: NCT01567839

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular buccal Infiltration injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular buccal Infiltration injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular buccal Infiltration injection
Study: NCT02966054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Physical Activity Intervention Group
Description: Print materials on exercise after cancer, Fitbit Flex for 12 weeks, and daily Text Messages for 12 weeks
Study: NCT04855084

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monolithic FDPs: after adjustment
Description: After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monolithic FDPs: after adjustment
Description: After the occlusal adjustment, Occlusal relationship recording of the 3-unit monolithic FDPs which was fabricated following the complete digital work-flow.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal fused porcelain FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal fused porcelain FDPs: before adjustment
Description: Before the occlusal adjustment, Occlusal relationship recording of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metal fused porcelain FDPs: after adjustment
Description: After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metal fused porcelain FDPs: after adjustment
Description: After the occlusal adjustment, digital occlusal relationship recording was done of the 3-unit metal fused porcelain FDPs which was fabricated following the complete conventional manufacturing procedure.